CXCL2 and neoplasm: Juzentaihoto treatment as well as the combination treatment (but not Gemcitabine treatment alone) showed a significant increase of the macrophage chemoattractant chemokines CCL2/MCP-1, CCL20/MIP3α, and CXCL2/MIP-2 in the supernatant of tumor cells (Figures 4A–C; Supplementary Figure S6).